← Human Trials & Peer-Reviewed Studies
Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure
Plain-language guide to PMID 15915407 (2005): double-blind randomized controlled trial study of BNP (Nesiritide), low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 15915407
- Journal
- The American journal of emergency medicine
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Peacock WF et al. (3 authors)
- DOI
- 10.1016/j.ajem.2004.11.002
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of BNP (Nesiritide) in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.
The Prospective Randomized Outcomes study of Acutely decompensated Congestive heart failure Treated Initially as Outpatients with Nesiritide (PROACTION) trial evaluated the safety of nesiritide administration in the emergency department in patients with decompensated heart failure.
Who Took Part
PubMed indexes the participants as older adults, both men and women.
Patients (N=237) were treated for at least 12 hours with standard care plus either intravenous nesiritide or placebo.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received BNP (Nesiritide).
The comparison arm used a placebo, so changes seen with BNP (Nesiritide) could be set against what happens without it.
What Was Measured
The Prospective Randomized Outcomes study of Acutely decompensated Congestive heart failure Treated Initially as Outpatients with Nesiritide (PROACTION) trial evaluated the safety of nesiritide administration in the emergency department in patients with decompensated heart failure.
Topics PubMed links to this paper include Blood Pressure, Emergency Service, Hospital, Heart Failure, Hypotension, Natriuretic Agents and Natriuretic Peptide, Brain.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide) in people with low blood pressure and orthostatic hypotension.
The publication is from 2005 (The American journal of emergency medicine), a journal based in United States.
More context: the BNP (Nesiritide) compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.